Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK A SOCINSKI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1740341726
CMS profile
1266401
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$421,935.74

296 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK A SOCINSKI

NPI 1740341726 · CMS profile ID 1266401

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK A SOCINSKI, NPI 1740341726, CMS profile ID 1266401. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARK A SOCINSKI, NPI 1740341726, CMS profile ID 1266401. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARK A SOCINSKI, NPI 1740341726, CMS profile ID 1266401, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740341726?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

296 matching records · $421,935.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 296 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 296.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $40.0011/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818636889 CMS
Lilly USA, LLC $23.7111/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818643897 CMS
Lilly USA, LLC $72.0011/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818651739 CMS
JAZZ PHARMACEUTICALS INC. $124.7311/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604803 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,460.0011/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820266705 CMS
JAZZ PHARMACEUTICALS INC. $110.0011/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604805 CMS
Genentech USA, Inc. $1,980.0011/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835945851 CMS
Genentech USA, Inc. $1,980.0011/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835945855 CMS
Lilly USA, LLC $14.3611/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818643901 CMS
Eli Lilly and Company $18,812.5011/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818600169 CMS
Genentech USA, Inc. $1,980.0011/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835945857 CMS
JAZZ PHARMACEUTICALS INC. $545.1811/04/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604391 CMS
JAZZ PHARMACEUTICALS INC. $34.9211/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604381 CMS
JAZZ PHARMACEUTICALS INC. $34.4211/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604383 CMS
JAZZ PHARMACEUTICALS INC. $92.4811/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604385 CMS
Amgen Inc. $433.0011/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826386921 CMS
G1 Therapeutics, Inc. $750.0010/29/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102485 CMS
Regeneron Healthcare Solutions, Inc. $55.0010/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809627009 CMS
Regeneron Healthcare Solutions, Inc. $55.0010/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809627011 CMS
Regeneron Healthcare Solutions, Inc. $20.5410/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809627013 CMS
Regeneron Healthcare Solutions, Inc. $2.4410/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809627015 CMS
Regeneron Healthcare Solutions, Inc. $181.1410/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809627017 CMS
G1 Therapeutics, Inc. $14.8410/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102445 CMS
G1 Therapeutics, Inc. $69.9910/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102453 CMS
G1 Therapeutics, Inc. $4,450.0010/27/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102469 CMS
G1 Therapeutics, Inc. $30.9910/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102501 CMS
G1 Therapeutics, Inc. $180.0010/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102503 CMS
G1 Therapeutics, Inc. $95.7010/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102507 CMS
G1 Therapeutics, Inc. $239.9810/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102511 CMS
G1 Therapeutics, Inc. $437.8810/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102515 CMS
JAZZ PHARMACEUTICALS INC. $221.7710/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845609115 CMS
Amgen Inc. $2,165.0010/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826386937 CMS
Lilly USA, LLC $3,075.0010/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818600181 CMS
Lilly USA, LLC $3,500.0010/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818634631 CMS
Amgen Inc. $2,165.0010/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826386931 CMS
Lilly USA, LLC $1,750.0010/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818666613 CMS
Lilly USA, LLC $94.5710/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818586105 CMS
Lilly USA, LLC $390.7210/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818608423 CMS
Lilly USA, LLC $47.0410/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818643895 CMS
Lilly USA, LLC $122.0310/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818651755 CMS
Amgen Inc. $2,165.0010/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826386925 CMS
Amgen Inc. $2,165.0010/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826386933 CMS
Coherus Biosciences Inc. $900.0010/19/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855095813 CMS
JAZZ PHARMACEUTICALS INC. $380.0010/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845601579 CMS
JAZZ PHARMACEUTICALS INC. $4,740.0010/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845601581 CMS
Lilly USA, LLC $7,000.0010/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818634627 CMS
Lilly USA, LLC $43.0210/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818634639 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,095.0010/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820266699 CMS
JAZZ PHARMACEUTICALS INC. $47.8510/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602991 CMS
JAZZ PHARMACEUTICALS INC. $62.0010/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602993 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $416,040.68 282
PY2020 $260,966.37 155
PY2021 $421,935.74 296
PY2022 $420,518.04 264
PY2023 $347,699.32 258
PY2024 $265,307.10 228
PY2025 $259,582.15 210

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $601,733.94 158
PY2024 Recipient $4,283.48 3
PY2024 Principal investigator $771,116.31 283
PY2023 Recipient $4,221.06 2
PY2023 Principal investigator $290,089.93 47
PY2022 Recipient $14,436.87 3
PY2022 Principal investigator $143,948.28 34
PY2021 Recipient $8,869.29 6
PY2021 Principal investigator $929,103.51 35
PY2020 Recipient $27,146.10 14
PY2020 Principal investigator $402,348.75 15
PY2019 Recipient $8,029.00 2
PY2019 Principal investigator $130,615.92 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

158 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeOne Medicines Ltd. $874.00 11/26/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341577
Principal investigator 1 BeOne Medicines Ltd. $250.00 09/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327329
Principal investigator 1 BeOne Medicines Ltd. $250.00 09/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327333
Principal investigator 1 BeOne Medicines Ltd. $6,076.00 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327051
Principal investigator 1 BeOne Medicines Ltd. $812.00 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327257
Principal investigator 1 BeOne Medicines Ltd. $3,042.00 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327277
Principal investigator 1 BeOne Medicines Ltd. $15,672.00 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327281
Principal investigator 1 BeOne Medicines Ltd. $20,790.00 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327313
Principal investigator 1 BeOne Medicines Ltd. $17,437.00 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327323
Principal investigator 1 BeOne Medicines Ltd. $328.99 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327341
Principal investigator 1 BeOne Medicines Ltd. $101.00 09/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331771
Principal investigator 1 BeOne Medicines Ltd. $500.00 09/22/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327117
Principal investigator 1 BeOne Medicines Ltd. $2,491.00 09/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327041
Principal investigator 1 BeOne Medicines Ltd. $203.00 09/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327295
Principal investigator 1 BeOne Medicines Ltd. $2,612.00 09/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327325
Principal investigator 1 BeOne Medicines Ltd. $3,038.00 09/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331767
Principal investigator 1 BeOne Medicines Ltd. $707.00 08/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327059
Principal investigator 1 BeOne Medicines Ltd. $203.00 08/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327091
Principal investigator 1 BeOne Medicines Ltd. $250.00 08/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327109
Principal investigator 1 BeOne Medicines Ltd. $2,970.00 08/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327111
Principal investigator 1 BeOne Medicines Ltd. $2,491.00 08/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327243
Principal investigator 1 BeOne Medicines Ltd. $338.00 08/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327339
Principal investigator 1 BeOne Medicines Ltd. $101.00 08/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327227
Principal investigator 1 BeOne Medicines Ltd. $16,408.99 08/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327223
Principal investigator 1 BeOne Medicines Ltd. $324.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327067
Principal investigator 1 BeOne Medicines Ltd. $750.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327217
Principal investigator 1 BeOne Medicines Ltd. $2,491.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327251
Principal investigator 1 BeOne Medicines Ltd. $135.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327255
Principal investigator 1 BeOne Medicines Ltd. $1,014.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327267
Principal investigator 1 BeOne Medicines Ltd. $972.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327269
Principal investigator 1 BeOne Medicines Ltd. $203.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327275
Principal investigator 1 BeOne Medicines Ltd. $2,323.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327289
Principal investigator 1 BeOne Medicines Ltd. $1,468.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327331
Principal investigator 1 BeOne Medicines Ltd. $406.00 08/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327337
Principal investigator 1 BeOne Medicines Ltd. $676.00 08/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327045
Principal investigator 1 BeOne Medicines Ltd. $250.00 07/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327061
Principal investigator 1 BeOne Medicines Ltd. $3,502.00 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327069
Principal investigator 1 BeOne Medicines Ltd. $1,513.00 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327119
Principal investigator 1 BeOne Medicines Ltd. $3,502.00 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327237
Principal investigator 1 BeOne Medicines Ltd. $1,513.00 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327283
Principal investigator 1 BeOne Medicines Ltd. $1,513.00 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327335
Principal investigator 1 BeOne Medicines Ltd. $3,502.00 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331777
Principal investigator 1 BeOne Medicines Ltd. $2,989.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326212
Principal investigator 1 BeOne Medicines Ltd. $2,633.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326224
Principal investigator 1 BeOne Medicines Ltd. $247.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326226
Principal investigator 1 BeOne Medicines Ltd. $2,970.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326236
Principal investigator 1 BeOne Medicines Ltd. $2,989.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326238
Principal investigator 1 BeOne Medicines Ltd. $34.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326244
Principal investigator 1 BeOne Medicines Ltd. $895.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326248
Principal investigator 1 BeOne Medicines Ltd. $2,989.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326250
Principal investigator 1 BeOne Medicines Ltd. $338.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331237
Principal investigator 1 BeOne Medicines Ltd. $247.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331241
Principal investigator 1 BeOne Medicines Ltd. $2,989.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331243
Principal investigator 1 BeOne Medicines Ltd. $338.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331269
Principal investigator 1 BeOne Medicines Ltd. $124.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331275
Principal investigator 1 BeOne Medicines Ltd. $203.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331277
Principal investigator 1 BeOne Medicines Ltd. $2,989.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338723
Principal investigator 1 BeOne Medicines Ltd. $2,989.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338727
Principal investigator 1 BeOne Medicines Ltd. $5,223.99 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338731
Principal investigator 1 BeOne Medicines Ltd. $2,970.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338736
Principal investigator 1 BeOne Medicines Ltd. $2,889.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338743
Principal investigator 1 BeOne Medicines Ltd. $324.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338747
Principal investigator 1 BeOne Medicines Ltd. $2,989.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338758
Principal investigator 1 BeOne Medicines Ltd. $2,491.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343016
Principal investigator 1 BeOne Medicines Ltd. $4,556.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343037
Principal investigator 1 BeOne Medicines Ltd. $34.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343050
Principal investigator 1 BeOne Medicines Ltd. $120.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343062
Principal investigator 1 BeOne Medicines Ltd. $203.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343070
Principal investigator 1 BeOne Medicines Ltd. $45.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343074
Principal investigator 1 BeOne Medicines Ltd. $2,612.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343078
Principal investigator 1 BeOne Medicines Ltd. $45.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343082
Principal investigator 1 BeOne Medicines Ltd. $4,982.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343085
Principal investigator 1 Genentech, Inc. $24,762.00 06/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211539695
Principal investigator 1 Genentech, Inc. $476.00 06/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211539700
Principal investigator 1 BeOne Medicines Ltd. $8,910.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326222
Principal investigator 1 BeOne Medicines Ltd. $203.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326228
Principal investigator 1 BeOne Medicines Ltd. $1,352.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190326240
Principal investigator 1 BeOne Medicines Ltd. $88.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331273
Principal investigator 1 BeOne Medicines Ltd. $7,836.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190338719
Principal investigator 1 BeOne Medicines Ltd. $648.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343033
Principal investigator 1 BeOne Medicines Ltd. $200.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343055
Principal investigator 1 BeOne Medicines Ltd. $9,963.99 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343059
Principal investigator 1 BeiGene, Ltd. $2,814.00 05/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322876
Principal investigator 1 BeiGene, Ltd. $2,814.00 05/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325030
Principal investigator 1 BeiGene, Ltd. $203.00 05/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325044
Principal investigator 1 BeiGene, Ltd. $676.00 05/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325056
Principal investigator 1 BeiGene, Ltd. $4,982.00 05/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325058
Principal investigator 1 BeiGene, Ltd. $1,380.00 05/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325014
Principal investigator 1 BeiGene, Ltd. $250.00 05/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325032
Principal investigator 1 BeiGene, Ltd. $1,200.00 05/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325618
Principal investigator 1 BeiGene, Ltd. $2,989.00 05/16/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320708
Principal investigator 1 BeiGene, Ltd. $338.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320680
Principal investigator 1 BeiGene, Ltd. $2,970.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320682
Principal investigator 1 BeiGene, Ltd. $5,224.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320684
Principal investigator 1 BeiGene, Ltd. $338.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320686
Principal investigator 1 BeiGene, Ltd. $7,473.03 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320692
Principal investigator 1 BeiGene, Ltd. $302.98 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320704
Principal investigator 1 BeiGene, Ltd. $203.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320706
Principal investigator 1 BeiGene, Ltd. $5,224.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320718
Principal investigator 1 BeiGene, Ltd. $203.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320720
Principal investigator 1 BeiGene, Ltd. $2,491.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320724
Principal investigator 1 BeiGene, Ltd. $2,612.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320726
Principal investigator 1 BeiGene, Ltd. $338.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320730
Principal investigator 1 BeiGene, Ltd. $2,491.01 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322884
Principal investigator 1 BeiGene, Ltd. $2,612.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322890
Principal investigator 1 BeiGene, Ltd. $2,491.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322894
Principal investigator 1 BeiGene, Ltd. $101.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322898
Principal investigator 1 BeiGene, Ltd. $250.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322946
Principal investigator 1 BeiGene, Ltd. $2,970.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322948
Principal investigator 1 BeiGene, Ltd. $406.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325022
Principal investigator 1 BeiGene, Ltd. $2,633.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325028
Principal investigator 1 BeiGene, Ltd. $5,940.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325046
Principal investigator 1 BeiGene, Ltd. $2,612.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325060
Principal investigator 1 BeiGene, Ltd. $5,639.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325596
Principal investigator 1 BeiGene, Ltd. $101.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325598
Principal investigator 1 BeiGene, Ltd. $4,982.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325602
Principal investigator 1 BeiGene, Ltd. $1,014.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325610
Principal investigator 1 BeiGene, Ltd. $609.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325612
Principal investigator 1 BeiGene, Ltd. $2,491.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325614
Principal investigator 1 BeiGene, Ltd. $2,970.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325622
Principal investigator 1 BeiGene, Ltd. $250.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325636
Principal investigator 1 BeiGene, Ltd. $2,633.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325640
Principal investigator 1 BeiGene, Ltd. $7,473.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325642
Principal investigator 1 BeiGene, Ltd. $2,970.00 05/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325648
Principal investigator 1 Genentech, Inc. $1,200.00 05/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211539722
Principal investigator 1 Mirati Therapeutics, Inc. $600.00 04/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530164
Principal investigator 1 BeiGene, Ltd. $676.00 04/25/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320694
Principal investigator 1 BeiGene, Ltd. $2,989.00 04/25/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320716
Principal investigator 1 BeiGene, Ltd. $2,989.00 04/25/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322882
Principal investigator 1 BeiGene, Ltd. $2,989.00 04/25/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325608
Principal investigator 1 BeiGene, Ltd. $250.00 04/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322896
Principal investigator 1 Genentech, Inc. $3,239.00 04/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211539725
Principal investigator 1 Genentech, Inc. $7,631.98 03/26/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211539714
Principal investigator 1 BeiGene, Ltd. $7,473.00 03/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319970
Principal investigator 1 BeiGene, Ltd. $101.00 03/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319998
Principal investigator 1 BeiGene, Ltd. $47.00 03/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320012
Principal investigator 1 BeiGene, Ltd. $1,014.00 03/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320068
Principal investigator 1 BeiGene, Ltd. $91.00 03/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324292
Principal investigator 1 BeiGene, Ltd. $2,989.00 03/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320098
Principal investigator 1 BeiGene, Ltd. $2,989.00 03/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324284
Principal investigator 1 BeiGene, Ltd. $2,989.00 03/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324650
Principal investigator 1 BeiGene, Ltd. $2,989.00 03/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324700
Principal investigator 1 BeiGene, Ltd. $2,989.00 02/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319950
Principal investigator 1 BeiGene, Ltd. $2,989.00 02/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320082
Principal investigator 1 BeiGene, Ltd. $2,989.00 02/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324164
Principal investigator 1 BeiGene, Ltd. $2,989.00 02/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324170
Principal investigator 1 BeiGene, Ltd. $2,989.00 02/21/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324304
Principal investigator 1 BeiGene, Ltd. $250.00 02/05/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324638
Principal investigator 1 BeiGene, Ltd. $47.00 02/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324172
Principal investigator 1 BeiGene, Ltd. $2,491.00 02/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324290
Principal investigator 1 BeiGene, Ltd. $338.00 02/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324658
Principal investigator 1 AstraZeneca UK Limited $2,044.58 01/29/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST) No dispute reported 06/30/2026 1185543224
Principal investigator 1 BeiGene, Ltd. $2,989.00 01/29/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319954
Principal investigator 1 BeiGene, Ltd. $2,989.00 01/29/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319992
Principal investigator 1 BeiGene, Ltd. $2,989.00 01/29/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319996
Principal investigator 1 BeiGene, Ltd. $250.00 01/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324280
Principal investigator 1 AstraZeneca Pharmaceuticals LP $500.00 01/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) No dispute reported 06/30/2026 1185543226
Principal investigator 1 Eli Lilly and Company $196,103.40 01/06/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1187871627